Detalles de la búsqueda
1.
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Blood
; 141(19): 2359-2371, 2023 05 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36626250
2.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica
; 109(4): 1149-1162, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37646671
3.
Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway.
Breast J
; 27(4): 314-321, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33660353
4.
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
Br J Haematol
; 184(6): 1006-1010, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30537212
5.
Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma.
Mod Pathol
; 32(5): 609-620, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30459475
6.
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
Am J Hematol
; 94(12): 1364-1373, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31571261
7.
Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis.
Int J Gynecol Pathol
; 36(1): 76-89, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27532149
8.
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2 ) in combination with lenalidomide and dexamethasone.
Am J Hematol
; 96(6): E193-E196, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33661527
9.
Immunohistochemical markers in lymphoid malignancies: Protein correlates of molecular alterations.
Semin Diagn Pathol
; 32(5): 381-91, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25769206
10.
The t(11;14)(q13;q32)/CCND1-IGH translocation in chronic lymphocytic leukaemia/small lymphocytic lymphoma: an unusual genetic aberration during the natural clinical course.
Histopathology
; 75(2): 291-294, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31021442
11.
Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing-Based Clonality Testing in B-Cell and Plasma Cell Neoplasms.
J Mol Diagn
; 26(3): 168-178, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38103591
12.
Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Detailed Description of the Technical Performance, Clinical Utility, and Platform Comparison.
J Mol Diagn
; 25(6): 352-366, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36963483
13.
Quantitative Off-Target Detection of Epstein-Barr Virus-Derived DNA in Routine Molecular Profiling of Hematopoietic Neoplasms by Panel-Based Hybrid-Capture Next-Generation Sequencing.
J Mol Diagn
; 24(1): 69-78, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34801704
14.
Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas.
Front Oncol
; 11: 739441, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34888236
15.
Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
Pathology
; 53(3): 385-399, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33674146
16.
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Blood Rev
; 46: 100732, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32771227
17.
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
J Mol Diagn
; 23(2): 181-199, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33217553
18.
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Lancet Haematol
; 8(6): e422-e432, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34048681
19.
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
JAMA Oncol
; 7(6): 862-868, 2021 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33856405
20.
Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant De Novo Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor.
J Hematol
; 9(4): 140-146, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33224395